Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiovascular Consequences of Inhaled Beta-agonists in Healthy Participants
NCT06027606Phase 1Completed
- Sponsor
- University of Alberta
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of salbutamol in asthma (3 arms), sponsored by University of Alberta. Primary endpoints: Pulse Wave Velocity and Flow Mediated Dilation. Started Sep 2023; status: completed.
02
Drugs
salbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06027606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027606.